留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

核苷酸适体在靶向给药系统中的应用进展

熊叶,  台宗光,  李强

downloadPDF
文章导航 > 药学实践与服务  > 2015 >  33(6): 490-493,532
熊叶, 台宗光, 李强. 核苷酸适体在靶向给药系统中的应用进展[J]. 药学实践与服务, 2015, 33(6): 490-493,532. doi: 10.3969/j.issn.1006-0111.2015.06.003
引用本文: 熊叶, 台宗光, 李强. 核苷酸适体在靶向给药系统中的应用进展[J]. 药学实践与服务, 2015, 33(6): 490-493,532. doi: 10.3969/j.issn.1006-0111.2015.06.003
shu
XIONG Ye, TAI ZongGuang, Li Qiang. Application progress of nucleic acid aptamers in targeted drug delivery system[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 490-493,532. doi: 10.3969/j.issn.1006-0111.2015.06.003
Citation: XIONG Ye, TAI ZongGuang, Li Qiang. Application progress of nucleic acid aptamers in targeted drug delivery system[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 490-493,532. doi: 10.3969/j.issn.1006-0111.2015.06.003
shu

核苷酸适体在靶向给药系统中的应用进展

doi: 10.3969/j.issn.1006-0111.2015.06.003
  • 1.

    第二军医大学附属长海医院, 上海 200433

  • 2.

    第二军医大学附属长海医院, 上海 200433;解放军92330部队医院, 山东 青岛 266102

基金项目: 国家自然科学基金项目(No.81170060)

Application progress of nucleic acid aptamers in targeted drug delivery system

  • 1.

    Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China

  • 2.

    Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China;Hospital of CPLA No.92330 Troop, Qingdao 266102, China

  • 摘要: 适体,即体外合成筛选得到的能特异性地与靶分子结合的一段寡核苷酸序列。由于其独特的性质,在靶向给药系统中有着广阔的应用前景,目前已成为靶向给药研究领域的热点。综述了适体在靶向给药系统中的优势及其应用进展,并对其应用前景和面临的问题进行分析。
    Abstract: Aptamers are single stranded oligonucleotides that have high affinity and specificity towards a wide range of target molecules. Owing to the indispensable advantages, aptamers have wildly prospects and have become a research hotspot in targeted drug delivery system (TDDS). In this article, application advantage and progress of aptamers in TDDS were briefly reviewed, the problems and prospects were also discussed.
  • [1] Tan W, Wang H, Chen Y, et al. Molecular aptamers for drug delivery[J]. Trends Biotechnol, 2011, 29(12): 634-640.
    [2] Ozalp VC, Eyidogan F, Oktem HA. Aptamer-gated nanoparticles for smart drug delivery[J]. Pharmaceuticals, 2011, 4(8): 1137-1157.
    [3] Taouji S, Dausse E, Evadé L, et al. Advances in binder identification and characterisation: the case of oligonucleotide aptamers[J]. N Biotechnol, 2012, 29(5): 550-554.
    [4] Famulok M, Hartig JS, Mayer G. Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy[J]. Chem Rev, 2007, 107(9): 3715-3743.
    [5] Lupold SE, Hicke BJ, Lin Y, et al. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen[J]. Cancer Res, 2002, 62(14): 4029-4033.
    [6] Farokhzad OC, Jon S, Khademhosseini A, et al. Nanoparticle-aptamer bioconjugates a new approach for targeting prostate cancer cells[J]. Cancer Res, 2004, 64(21): 7668-7672.
    [7] Bagalkot V, Farokhzad OC, Langer R, et al. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform[J]. Angew Chem Int Ed, 2006, 45(48): 8149-8152.
    [8] Kraus E, James W, Barclay AN. Cutting edge: novel RNA ligands able to bind CD4 antigen and inhibit CD4+ T lymphocyte function[J]. J Immunol, 1998, 160(11): 5209-5212.
    [9] Guo S, Tschammer N, Mohammed S, et al. Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA[J]. Hum Gene Ther, 2005, 16(9): 1097-1110.
    [10] Khaled A, Guo S, Li F, et al. Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology[J]. Nano Lett, 2005, 5(9): 1797-1808.
    [11] Singh AB, Harris RC. Autocrine, paracrine and juxtacrine signaling by EGFR ligands[J]. Cell Signal, 2005, 17(10): 1183-1193.
    [12] Li N, Larson T, Nguyen HH, et al. Directed evolution of gold nanoparticle delivery to cells[J]. Chem Commun, 2010, 46(3): 392-394.
    [13] Prebet T, Lhoumeau A-C, Arnoulet C, et al. The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome[J]. Blood, 2010, 116(13): 2315-2323.
    [14] Shangguan D, Li Y, Tang Z, et al. Aptamers evolved from live cells as effective molecular probes for cancer study[J]. P Natl Acad Sci USA, 2006, 103(32): 11838-11843.
    [15] Xiao Z, Shangguan D, Cao Z, et al. Cell-specific internalization study of an aptamer from whole cell selection[J]. Chem Eur J, 2008, 14(6): 1769-1775.
    [16] Huang YF, Shangguan D, Liu H, et al. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells[J]. Chem Bio Chem, 2009, 10(5): 862-868.
    [17] o'donoghue MB. A liposome-based nanostructure for aptamer directed delivery[J]. Chem Commun, 2010, 46(2): 249-251.
    [18] 胡 萍. 肿瘤发生和 MUC1 及 Survivin 研究进展[J]. 中国医药指南, 2013, 11(1): 69-70.
    [19] Altschuler Y, Kinlough CL, Poland PA, et al. Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state[J]. Mol Biol Cell, 2000, 11(3): 819-831.
    [20] Gendler SJ. MUC1, the renaissance molecule[J]. J Mammary Gland Biol Neoplasia, 2001, 6(3): 339-353.
    [21] Ferreira CS, Cheung MC, Missailidis S, et al. Phototoxic aptamers selectively enter and kill epithelial cancer cells[J]. Nucleic Acids Res, 2009, 37(3): 866-876.
    [22] Do Kwon Y, Finzi A, Wu X, et al. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops[J]. P Natl Acad Sci USA, 2012, 109(15): 5663-5668.
    [23] Zhou J, Li H, Li S, et al. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy[J]. Mol Ther, 2008, 16(8): 1481-1489.
    [24] Reyes-Reyes EM, Teng Y, Bates PJ. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism[J]. Cancer Res, 2010, 70(21): 8617-8629.
    [25] Cao Z, Tong R, Mishra A, et al. Reversible cell-specific drug delivery with aptamer-functionalized liposomes[J]. Angew Chem Int Ed, 2009, 48(35): 6494-6498.
    [26] 胡艳玲, 史爱欣, 傅得兴, 等. 哌加他尼钠的药理作用和临床评价[J]. 中国新药杂志, 2007, 16(7): 573-576.
    [27] Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy[J]. Graef Arch Clin Exp, 2010, 248(7): 915-930.
    [28] Proske D, Gilch S, Wopfner F, et al. Prion-protein-specific aptamer reduces PrPSc formation[J]. Chem Bio Chem, 2002, 3(8): 717-725.
    [29] Jeon SH, Kayhan B, Ben-Yedidia T, et al. A DNA aptamer prevents influenza infection by blocking the receptor binding region of the viral hemagglutinin[J]. J Biol Chem, 2004, 279(46): 48410-48419.
    [30] Becker RC, Chan MY. REG-1, a regimen comprising RB-006, a Factor Ⅸa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis[J]. Curr Opin Mol Ther, 2009, 11(6): 707-715.
  • [1] 徐飞, 陈瑾, 鲁育含, 李志勇.  肠道菌群参与糖尿病肾病的机制研究进展 . 药学实践与服务, 2024, 42(5): 181-184, 197. doi: 10.12206/j.issn.2097-2024.202312023
    [2] 丁千雪, 尚圣兰, 余梦辰, 余爱荣.  机器学习在肾病综合征患者他克莫司个体化用药中的应用 . 药学实践与服务, 2024, 42(6): 227-230, 243. doi: 10.12206/j.issn.2097-2024.202310007
    [3] 王耀振, 徐灿, 吕顺莉, 田泾, 张东炜.  钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 1-7. doi: 10.12206/j.issn.2097-2024.202306040
    [4] 陈炳辰, 佟达丰, 万苗, 闫飞虎, 姚建忠.  UPLC-MS/MS法测定小鼠血浆中紫杉醇脂肪酸酯前药及其药代动力学研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404082
    [5] 张林晨, 张小琴, 张俊平.  山楂酸药理作用的研究进展 . 药学实践与服务, 2024, 42(5): 185-189. doi: 10.12206/j.issn.2097-2024.202307052
    [6] 马兹芬, 许维恒, 金煜翔, 薛磊.  食管癌的靶向治疗与免疫治疗研究进展 . 药学实践与服务, 2024, 42(6): 231-237. doi: 10.12206/j.issn.2097-2024.202306008
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  3074
  • HTML全文浏览量:  250
  • PDF下载量:  291
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-11-04
  • 修回日期:  2014-12-24

核苷酸适体在靶向给药系统中的应用进展

doi: 10.3969/j.issn.1006-0111.2015.06.003
  • 1. 第二军医大学附属长海医院, 上海 200433
  • 2. 第二军医大学附属长海医院, 上海 200433;解放军92330部队医院, 山东 青岛 266102
    • 基金项目:  国家自然科学基金项目(No.81170060)
  • 收稿日期: 2013-11-04
  • 修回日期: 2014-12-24

摘要: 适体,即体外合成筛选得到的能特异性地与靶分子结合的一段寡核苷酸序列。由于其独特的性质,在靶向给药系统中有着广阔的应用前景,目前已成为靶向给药研究领域的热点。综述了适体在靶向给药系统中的优势及其应用进展,并对其应用前景和面临的问题进行分析。

English Abstract

熊叶, 台宗光, 李强. 核苷酸适体在靶向给药系统中的应用进展[J]. 药学实践与服务, 2015, 33(6): 490-493,532. doi: 10.3969/j.issn.1006-0111.2015.06.003
引用本文: 熊叶, 台宗光, 李强. 核苷酸适体在靶向给药系统中的应用进展[J]. 药学实践与服务, 2015, 33(6): 490-493,532. doi: 10.3969/j.issn.1006-0111.2015.06.003
shu
XIONG Ye, TAI ZongGuang, Li Qiang. Application progress of nucleic acid aptamers in targeted drug delivery system[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 490-493,532. doi: 10.3969/j.issn.1006-0111.2015.06.003
Citation: XIONG Ye, TAI ZongGuang, Li Qiang. Application progress of nucleic acid aptamers in targeted drug delivery system[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 490-493,532. doi: 10.3969/j.issn.1006-0111.2015.06.003
shu

    全文HTML

参考文献 (30)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计